The Issue
Parkinson’s is primarily a movement-related neurodegenerative disorder, known for the loss of dopaminergic neurons in the part of the brain called the substantia nigra.
cases worldwide
annual growth rate
cases in the U.S.
new cases annually in the U.S.
Our Focus
ATED Diagnostics, with Hebrew University in Jerusalem, has developed a new transfer RNA fragment (tRF), non-invasive blood based diagnostic test for Parkinson’s Disease that detects Parkinson’s Disease in its earliest stages. It will be studied in a planned clinical trial.
Our Team
Our researchers are relentlessly advancing cutting-edge diagnostics and breakthroughs to improve quality of life and bring hope to those affected with Parkinson’s disease.
News
ATED Therapeutics Named Finalist for the 2026 Asper PrizeJerusalem, Israel — May 20, 2026ATED Therapeutics announced today that it has been selected as a finalist for the 2026 Asper Prize, the Hebrew University of Jerusalem’s flagship award recognizing breakthrough innovation and global impact. This distinction places ATED Therapeutics among a select group of ventures chosen Continue Reading »
Read MoreThe new test can be used to identify pre-symptomatic patients with Parkinson’s and can monitor progression of the disease.
Read MoreThe new test can be used to identify pre-symptomatic patients with Parkinson’s disease and can measure progression of the disease.
Read More
Contact Us
Reach out to our team to learn how we are advancing innovative, research-driven solutions in Parkinson’s treatment, and discover how we can collaborate, answer your questions, or support your efforts in bringing meaningful progress to patients and families impacted by the disease.